Related Experiment Videos
Achieving Rapid Remission With Guselkumab in a Moderately Active Ulcerative Colitis Patient With High Infectious Risk
Nozomi Furuichi1, Yuki Itoi1, Keiichi Oshima1
1Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, JPN.
Abstract:
Ulcerative colitis (UC) with prior inadequate response to advanced therapy (AT-IR) that requires hospitalization is particularly challenging to manage, especially in cases where a high risk of infection limits the use of immunosuppressive agents. A 32-year-old male patient with pancolitis-type UC was refractory to glucocorticosteroids, infliximab, and tacrolimus. His clinical course was complicated by septic shock and invasive candidiasis. Antifungal therapy limited the use of upadacitinib due to drug-drug interactions. After achieving infection control, intravenous guselkumab (200 mg) was initiated. The patient's stool frequency normalized, and hematochezia resolved within two weeks. The patient achieved clinical remission, and he was then discharged. In conclusion, guselkumab achieved clinical remission in a patient with active UC with AT-IR, in whom the risk of infection was high and other advanced therapies were restricted.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Ulcerative Colitis
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents